HRP20192100T1 - Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe - Google Patents
Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe Download PDFInfo
- Publication number
- HRP20192100T1 HRP20192100T1 HRP20192100TT HRP20192100T HRP20192100T1 HR P20192100 T1 HRP20192100 T1 HR P20192100T1 HR P20192100T T HRP20192100T T HR P20192100TT HR P20192100 T HRP20192100 T HR P20192100T HR P20192100 T1 HRP20192100 T1 HR P20192100T1
- Authority
- HR
- Croatia
- Prior art keywords
- synergistic combination
- lymphoma
- use according
- sequence
- seq
- Prior art date
Links
- 229940125814 BTK kinase inhibitor Drugs 0.000 title 1
- 239000011885 synergistic combination Substances 0.000 claims 15
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 5
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 5
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 5
- 229960001507 ibrutinib Drugs 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (15)
1. Sinergistička kombinacija koja sadrži antitijelo specifično za CD19 naznačena time što navedeno antitijelo sadrži HCDR1 područje sa sekvencom SYVMH (SEQ ID NO: 1), HCDR2 područje sa sekvencom NPYNDG (SEQ ID NO: 2), HCDR3 područje sa sekvencom GTYYYGTRVFDY (SEQ ID NO: 3), LCDR1 područje sa sekvencom RSSKSLQNVNGNTYLY (SEQ ID NO: 4), LCDR2 područje sa sekvencom RMSNLNS (SEQ ID NO: 5) i LCDR3 područje sa sekvencom MQHLEYPIT (SEQ ID NO: 6) i ibrutinib, za uporabu u liječenju ne-Hodgkinovog limfoma, kronične limfocitne leukemije i/ili akutne limfoblastne leukemije.
2. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time što antitijelo sadrži varijabilan teški lanac sa sekvencom
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY
NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG QGTLVTVSS (SEQ ID NO: 10) i varijabilan laki lanac sa sekvencom
3. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevima 1 ili 2, naznačena time što antitijelo sadrži konstantnu domenu teškog lanca sa sekvencom
4. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što antitijelo sadrži konstantnu domenu lakog lanca sa sekvencom
5. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se navedeno antitijelo specifično za CD19 i ibrutinib primjenjuju odvojeno.
6. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se ibrutinib primjenjuje prije primjene antitijela specifičnog za CD19.
7. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se navedeno antitijelo specifično za CD19 i ibrutinib primjenjuju istovremeno.
8. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se navedeno antitijelo specifično za CD19 i ibrutinib primjenjuju u isto vrijeme, pri čemu su oba lijeka aktivna u pacijentu u isto vrijeme.
9. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, za uporabu u liječenju kronične limfocitne leukemije.
10. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, za uporabu u liječenju akutne limfoblastne leukemije.
11. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, za uporabu u liječenju ne-Hodgkinovog limfoma, pri čemu je ne-Hodgkinov limfom odabran iz grupe koja se sastoji od folikularnog limfoma, limfoma malih limfocita, limfoidnog tkiva povezanog sa sluznicom, marginalne zone, difuznih velikih B stanica, Burkittova i stanica plašta.
12. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 11, naznačena time što je ne-Hodgkinov limfom folikularni limfom.
13. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 11, naznačena time što je ne-Hodgkinov limfom difuzni limfom velikih B stanica.
14. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 11, naznačena time što je ne-Hodgkinov limfom Burkittov limfom.
15. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 11, naznačena time što je ne-Hodgkinov limfom limfom stanica plašta.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15169124 | 2015-05-26 | ||
| EP15196860 | 2015-11-27 | ||
| EP16725504.1A EP3302550B1 (en) | 2015-05-26 | 2016-05-25 | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| PCT/EP2016/061744 WO2016189014A1 (en) | 2015-05-26 | 2016-05-25 | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192100T1 true HRP20192100T1 (hr) | 2020-02-21 |
Family
ID=56084030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192100TT HRP20192100T1 (hr) | 2015-05-26 | 2019-11-22 | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10617691B2 (hr) |
| EP (2) | EP3302550B1 (hr) |
| JP (3) | JP6916741B2 (hr) |
| KR (1) | KR20180004286A (hr) |
| CN (2) | CN114601931B (hr) |
| AU (3) | AU2016266708B2 (hr) |
| CA (1) | CA2986175A1 (hr) |
| CY (1) | CY1122298T1 (hr) |
| DK (1) | DK3302550T3 (hr) |
| ES (1) | ES2754431T3 (hr) |
| HK (1) | HK1251152B (hr) |
| HR (1) | HRP20192100T1 (hr) |
| HU (1) | HUE046328T2 (hr) |
| IL (2) | IL255377B (hr) |
| LT (1) | LT3302550T (hr) |
| PL (1) | PL3302550T3 (hr) |
| PT (1) | PT3302550T (hr) |
| RS (1) | RS59605B1 (hr) |
| RU (1) | RU2756010C2 (hr) |
| SI (1) | SI3302550T1 (hr) |
| WO (1) | WO2016189014A1 (hr) |
| ZA (1) | ZA201707867B (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| CN116120454A (zh) * | 2017-01-05 | 2023-05-16 | 上海煦顼技术有限公司 | 人源化抗cd19抗体及其与嵌合抗原受体的用途 |
| US11634488B2 (en) | 2017-07-10 | 2023-04-25 | International—Drug—Development—Biotech | Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics |
| JP7548587B2 (ja) * | 2018-09-07 | 2024-09-10 | アイタブメッド （エイチケイ） リミテッド | 二重特異性抗原結合タンパク質及びその使用 |
| KR20200030337A (ko) * | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114786723A (zh) * | 2019-10-31 | 2022-07-22 | 莫佛塞斯公司 | 序贯抗cd19疗法 |
| CA3203587A1 (en) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| WO2022115120A1 (en) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| WO2024037594A1 (en) * | 2022-08-19 | 2024-02-22 | Beijing Innocare Pharma Tech Co., Ltd. | Combination treatment with orelabrutinib and tafasitamab |
| KR102655236B1 (ko) | 2024-01-02 | 2024-04-08 | 한화시스템(주) | 빔 조향범위 확장 구조를 가지는 저궤도 통신위성 배열안테나 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| WO2002022212A2 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| EP2270050B1 (en) | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anti-CD19 antibodies with reduced immunogenicity |
| ES2402591T3 (es) | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| EP2066349B1 (en) | 2006-09-08 | 2012-03-28 | MedImmune, LLC | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
| EP2201840B1 (en) | 2006-09-22 | 2011-11-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
| EP2708557A1 (en) | 2007-05-30 | 2014-03-19 | Xencor, Inc. | Method and compositions for inhibiting CD32B expressing cells |
| LT2211904T (lt) | 2007-10-19 | 2016-11-25 | Seattle Genetics, Inc. | Cd19 surišantys agentai ir jų panaudojimas |
| US8679492B2 (en) | 2009-02-23 | 2014-03-25 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to CD19 and their uses |
| WO2010151341A1 (en) | 2009-06-24 | 2010-12-29 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| CA3113343A1 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| DK2718270T3 (da) | 2011-06-10 | 2022-08-01 | Merck Patent Gmbh | Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| KR20200058583A (ko) * | 2011-08-16 | 2020-05-27 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| HUE058855T2 (hu) | 2011-08-16 | 2022-09-28 | Morphosys Ag | Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával |
| TWI573792B (zh) * | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| JP2015526520A (ja) * | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体 |
| WO2014113932A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
-
2016
- 2016-05-25 CN CN202210162934.XA patent/CN114601931B/zh active Active
- 2016-05-25 SI SI201630518T patent/SI3302550T1/sl unknown
- 2016-05-25 AU AU2016266708A patent/AU2016266708B2/en active Active
- 2016-05-25 EP EP16725504.1A patent/EP3302550B1/en active Active
- 2016-05-25 EP EP19192976.9A patent/EP3603672A1/en active Pending
- 2016-05-25 RU RU2017143166A patent/RU2756010C2/ru active
- 2016-05-25 CA CA2986175A patent/CA2986175A1/en active Pending
- 2016-05-25 RS RS20191485A patent/RS59605B1/sr unknown
- 2016-05-25 PT PT167255041T patent/PT3302550T/pt unknown
- 2016-05-25 WO PCT/EP2016/061744 patent/WO2016189014A1/en active Application Filing
- 2016-05-25 CN CN201680030141.5A patent/CN107660151B/zh active Active
- 2016-05-25 PL PL16725504T patent/PL3302550T3/pl unknown
- 2016-05-25 KR KR1020177037023A patent/KR20180004286A/ko not_active Application Discontinuation
- 2016-05-25 ES ES16725504T patent/ES2754431T3/es active Active
- 2016-05-25 LT LT16725504T patent/LT3302550T/lt unknown
- 2016-05-25 JP JP2017560705A patent/JP6916741B2/ja active Active
- 2016-05-25 DK DK16725504T patent/DK3302550T3/da active
- 2016-05-25 HU HUE16725504A patent/HUE046328T2/hu unknown
- 2016-05-25 US US15/572,914 patent/US10617691B2/en active Active
-
2017
- 2017-11-01 IL IL255377A patent/IL255377B/en unknown
- 2017-11-20 ZA ZA2017/07867A patent/ZA201707867B/en unknown
-
2018
- 2018-08-16 HK HK18110551.0A patent/HK1251152B/zh unknown
-
2019
- 2019-11-19 CY CY20191101214T patent/CY1122298T1/el unknown
- 2019-11-22 HR HRP20192100TT patent/HRP20192100T1/hr unknown
-
2020
- 2020-03-02 US US16/806,353 patent/US20200206228A1/en not_active Abandoned
-
2021
- 2021-06-02 JP JP2021092970A patent/JP2021152029A/ja active Pending
- 2021-10-20 IL IL287433A patent/IL287433A/en unknown
-
2022
- 2022-04-28 AU AU2022202796A patent/AU2022202796B2/en active Active
-
2023
- 2023-01-17 JP JP2023005159A patent/JP2023058502A/ja active Pending
- 2023-02-01 US US18/162,955 patent/US20240009196A1/en active Pending
-
2024
- 2024-02-16 AU AU2024201029A patent/AU2024201029A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
| HRP20210838T1 (hr) | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe | |
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| HRP20211291T1 (hr) | Kombinacije i njihove primjene | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| HRP20231021T1 (hr) | Protutijela anti-cd38 za liječenje akutne limfoblastične leukemije | |
| RU2015110981A (ru) | Комбинации и их применение | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| JP2017507954A5 (hr) | ||
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| NZ740221A (en) | St2l antagonists and methods of use | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| EA031493B9 (ru) | Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл) | |
| MX2014005996A (es) | Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. | |
| JP2019533682A5 (hr) | ||
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
| PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo |